Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

2012;5(3):325-340. The distinct pattern of expression in postembryonic tissues may be of importance for EPHA3 as a novel focus for targeted therapy, as with scant receptor expression in normal ...

Since our discovery that the insulin receptor is an insulin-stimulated receptor tyrosine kinase, the Kahn lab has focused on understanding how this event activates the complex signaling network that ...

MET is a tyrosine kinase receptor that has an essential role in normal cell development. 5 Savolitinib blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of ...

Tyrosine kinase inhibitors are the gold-standard therapy for CML, but one in five individuals with CML do not respond optimally to multiple lines of treatment (Fig. 1b). Our study also suggested ...

Riess, University of California, UC Davis Comprehensive Cancer Center, CA, US LB416 Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma ...